PL2383297T3 - Zoptymalizowane przeciwciała ukierunkowane na CD19 - Google Patents
Zoptymalizowane przeciwciała ukierunkowane na CD19Info
- Publication number
- PL2383297T3 PL2383297T3 PL11173336T PL11173336T PL2383297T3 PL 2383297 T3 PL2383297 T3 PL 2383297T3 PL 11173336 T PL11173336 T PL 11173336T PL 11173336 T PL11173336 T PL 11173336T PL 2383297 T3 PL2383297 T3 PL 2383297T3
- Authority
- PL
- Poland
- Prior art keywords
- target
- optimized antibodies
- antibodies
- optimized
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82236206P | 2006-08-14 | 2006-08-14 | |
EP11173336.6A EP2383297B8 (en) | 2006-08-14 | 2007-08-14 | Optimized antibodies that target CD19 |
EP07840953.9A EP2059536B1 (en) | 2006-08-14 | 2007-08-14 | Optimized antibodies that target cd19 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2383297T3 true PL2383297T3 (pl) | 2013-06-28 |
Family
ID=39083071
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL11173336T PL2383297T3 (pl) | 2006-08-14 | 2007-08-14 | Zoptymalizowane przeciwciała ukierunkowane na CD19 |
PL07840953T PL2059536T3 (pl) | 2006-08-14 | 2007-08-14 | Zoptymalizowane przeciwciała ukierunkowane na CD19 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL07840953T PL2059536T3 (pl) | 2006-08-14 | 2007-08-14 | Zoptymalizowane przeciwciała ukierunkowane na CD19 |
Country Status (20)
Country | Link |
---|---|
US (7) | US8524867B2 (pl) |
EP (2) | EP2059536B1 (pl) |
JP (4) | JP5825756B2 (pl) |
AU (1) | AU2007285976B2 (pl) |
CA (1) | CA2658557C (pl) |
DK (2) | DK2059536T3 (pl) |
ES (2) | ES2457072T3 (pl) |
FI (1) | FIC20220006I1 (pl) |
FR (1) | FR22C1007I2 (pl) |
HK (1) | HK1131168A1 (pl) |
HR (2) | HRP20130314T2 (pl) |
HU (1) | HUS2200007I1 (pl) |
LT (1) | LTPA2022503I1 (pl) |
ME (1) | ME01786B (pl) |
NL (1) | NL301163I2 (pl) |
PL (2) | PL2383297T3 (pl) |
PT (2) | PT2059536E (pl) |
RS (2) | RS52775B9 (pl) |
SI (2) | SI2383297T1 (pl) |
WO (1) | WO2008022152A2 (pl) |
Families Citing this family (139)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4342995A2 (en) | 2006-03-31 | 2024-03-27 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
ME01786B (me) | 2006-08-14 | 2014-09-20 | Xencor Inc | Optimizovana antitela usmerena na cd19 |
EP2176298B1 (en) | 2007-05-30 | 2017-11-15 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
MX2010003450A (es) | 2007-09-26 | 2010-04-27 | Chugai Pharmaceutical Co Ltd | Region constante de anticuerpo modificada. |
EP3127921A1 (en) | 2007-09-26 | 2017-02-08 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substition in cdr |
CA2702555A1 (en) | 2007-10-19 | 2009-04-23 | Seattle Genetics, Inc. | Cd19 binding agents and uses thereof |
KR102269708B1 (ko) | 2008-04-11 | 2021-06-25 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
EP2282769A4 (en) | 2008-04-29 | 2012-04-25 | Abbott Lab | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES |
KR20110016959A (ko) | 2008-06-03 | 2011-02-18 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
JP2011523853A (ja) | 2008-06-03 | 2011-08-25 | アボット・ラボラトリーズ | 二重可変ドメイン免疫グロブリン及びその使用 |
SG192489A1 (en) | 2008-07-08 | 2013-08-30 | Abbott Lab | Prostaglandin e2 dual variable domain immunoglobulins and uses thereof |
PL3330293T3 (pl) * | 2008-11-07 | 2020-02-28 | Amgen Research (Munich) Gmbh | Leczenie ostrej białaczki limfoblastycznej wieku dziecięcego za pomocą biswoistych przeciwciał przeciwko cd3xcd19 |
ME02363B (me) | 2008-11-07 | 2016-06-20 | Amgen Res Munich Gmbh | Liječenje akutne limfoblastične leukemije |
EP3279326B1 (en) | 2009-06-02 | 2020-10-14 | Regeneron Pharmaceuticals, Inc. | Fucosylation-deficient cells |
BR112012008833A2 (pt) | 2009-10-15 | 2015-09-08 | Abbott Lab | imunoglobulinas de dominio variavel duplo e usos das mesmas |
UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
BR112012030179A8 (pt) | 2010-05-27 | 2023-03-14 | Merck Sharp & Dohme | Polipeptídeo contendo fc |
EP2409993A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC function with improved glycosylation profile |
EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
EP2409989A1 (en) * | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Method to improve glycosylation profile for antibody |
MX341579B (es) | 2010-08-03 | 2016-08-25 | Abbvie Inc * | Inmunoglobulinas de dominio variable doble y usos de las mismas. |
AU2011293253B2 (en) | 2010-08-26 | 2014-12-11 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
AU2011337704B2 (en) | 2010-11-30 | 2017-06-15 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
KR102147548B1 (ko) | 2011-02-25 | 2020-08-24 | 추가이 세이야쿠 가부시키가이샤 | FcγRIIb 특이적 Fc 항체 |
CN103827300A (zh) * | 2011-06-30 | 2014-05-28 | 中外制药株式会社 | 异源二聚化多肽 |
JP6184952B2 (ja) | 2011-08-16 | 2017-08-23 | モルフォシス・アーゲー | 抗cd19抗体とナイトロゲンマスタードとの併用療法 |
HRP20220224T1 (hr) * | 2011-08-16 | 2022-04-29 | Morphosys Ag | Kombinacijska terapija s protutijelom anti-cd19 i dušičnim alkilirajućim agensom |
CN108144058A (zh) | 2011-09-30 | 2018-06-12 | 中外制药株式会社 | 促进抗原消除的抗原结合分子 |
EP3939996A1 (en) | 2011-09-30 | 2022-01-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
TW201817744A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之FcRn結合域的治療性抗原結合分子 |
CN113416256A (zh) | 2011-11-30 | 2021-09-21 | 中外制药株式会社 | 包含进入细胞内以形成免疫复合体的搬运体(载体)的药物 |
US11147852B2 (en) | 2011-12-23 | 2021-10-19 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
CA2861610A1 (en) | 2011-12-30 | 2013-07-04 | Abbvie Inc. | Dual specific binding proteins directed against il-13 and/or il-17 |
TW202015731A (zh) | 2012-02-24 | 2020-05-01 | 日商中外製藥股份有限公司 | 經FcγRIIB促進抗原消失之抗原結合分子 |
EP2827902A4 (en) * | 2012-03-12 | 2016-01-20 | Medimmune Llc | TREATMENT OF MULTIPLE SCLEROSIS WITH ANTI-CD19 ANTIBODY |
JP2015517655A (ja) * | 2012-05-01 | 2015-06-22 | ザ チルドレンズ ホスピタル オブフィラデルフィア | Bリンパ性悪性疾患を治療するための組成物および方法 |
EP3279315A3 (en) | 2012-05-25 | 2018-02-28 | Cellectis | Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells |
WO2013187495A1 (ja) | 2012-06-14 | 2013-12-19 | 中外製薬株式会社 | 改変されたFc領域を含む抗原結合分子 |
TWI717591B (zh) | 2012-08-24 | 2021-02-01 | 日商中外製藥股份有限公司 | FcγRIIb特異性Fc區域變異體 |
US11236168B2 (en) | 2012-08-24 | 2022-02-01 | Chugai Seiyaku Kabushiki Kaisha | Mouse FcγammaRII-specific Fc antibody |
HUE042731T2 (hu) | 2012-10-12 | 2019-07-29 | Adc Therapeutics Sa | Pirrolobenzodiazepin-antitest konjugátumok |
LT2839860T (lt) | 2012-10-12 | 2019-07-10 | Medimmune Limited | Pirolobenzodiazepinai ir jų konjugatai |
EP2906296B1 (en) | 2012-10-12 | 2018-03-21 | ADC Therapeutics SA | Pyrrolobenzodiazepine-antibody conjugates |
TW202210507A (zh) | 2012-11-01 | 2022-03-16 | 美商艾伯維有限公司 | 抗-vegf/dll4雙重可變區域免疫球蛋白及其用途 |
BR112015010722A2 (pt) | 2012-11-09 | 2017-08-22 | Pfizer | Anticorpos específicos de fator de crescimento derivado de plaquetas de isoforma b e composições e usos dos mesmos |
JP6433297B2 (ja) | 2012-12-27 | 2018-12-05 | 中外製薬株式会社 | ヘテロ二量化ポリペプチド |
WO2014165115A1 (en) * | 2013-03-12 | 2014-10-09 | Decimmune Therapeutics, Inc. | Humanized anti-n2 antibodies |
CA2905181C (en) | 2013-03-13 | 2020-06-02 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy |
US9062108B2 (en) | 2013-03-15 | 2015-06-23 | Abbvie Inc. | Dual specific binding proteins directed against IL-1 and/or IL-17 |
US9561291B2 (en) * | 2013-03-15 | 2017-02-07 | Imre Kovesdi | Methods of targeting T-cells to tumors |
KR20210130260A (ko) | 2013-04-02 | 2021-10-29 | 추가이 세이야쿠 가부시키가이샤 | Fc영역 개변체 |
CN109897100A (zh) * | 2013-05-13 | 2019-06-18 | 瑟勒提斯公司 | Cd19特异性嵌合抗原受体及其用途 |
US11077144B2 (en) | 2013-05-13 | 2021-08-03 | Cellectis | CD19 specific chimeric antigen receptor and uses thereof |
JP6534615B2 (ja) | 2013-09-27 | 2019-06-26 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
WO2015052534A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
KR102366076B1 (ko) | 2013-11-13 | 2022-02-21 | 화이자 인코포레이티드 | 종양 괴사 인자-유사 리간드 1a 특이적 항체 및 그의 조성물 및 용도 |
CN105263959A (zh) * | 2013-12-31 | 2016-01-20 | 财团法人生物技术开发中心 | 抗vegf抗体及其用途 |
WO2015109212A1 (en) | 2014-01-17 | 2015-07-23 | Pfizer Inc. | Anti-il-2 antibodies and compositions and uses thereof |
IL249533A0 (en) * | 2014-06-16 | 2017-02-28 | Xencor Inc | Treatment of chronic lymphocytic leukemia |
CN106794231A (zh) * | 2014-06-16 | 2017-05-31 | 赞科股份有限公司 | 用于慢性淋巴细胞性白血病(cll)的治疗 |
WO2016037644A1 (en) | 2014-09-10 | 2016-03-17 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
USD791796S1 (en) * | 2014-09-11 | 2017-07-11 | Express Scripts, Inc. | Display screen with a graphical user interface |
USD801353S1 (en) * | 2014-09-11 | 2017-10-31 | Express Scripts, Inc. | Display screen with a graphical user interface |
USD791797S1 (en) * | 2014-09-11 | 2017-07-11 | Express Scripts, Inc. | Display screen with a graphical user interface |
GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
CR20170194A (es) | 2014-11-14 | 2017-07-10 | Hoffmann La Roche | Moleculas de unión a antígeno que comprenden un trímero de ligando de la familia de tnf |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
MA41294A (fr) | 2014-12-19 | 2017-11-08 | Chugai Pharmaceutical Co Ltd | Anticorps anti-myostatine, polypeptides contenant des variants de régions fc, et procédés d'utilisation |
CN114773470A (zh) | 2015-02-05 | 2022-07-22 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il-8-结合抗体及其应用 |
EP3973980A1 (en) | 2015-03-31 | 2022-03-30 | F. Hoffmann-La Roche AG | Antigen binding molecules comprising a trimeric tnf family ligand |
AR104368A1 (es) | 2015-04-03 | 2017-07-19 | Lilly Co Eli | Anticuerpos biespecíficos anti-cd20- / anti-baff |
WO2016189014A1 (en) | 2015-05-26 | 2016-12-01 | Morphosys Ag | Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
WO2017015619A1 (en) | 2015-07-23 | 2017-01-26 | The Regents Of The University Of California | Antibodies to coagulation factor xia and uses thereof |
IL257345B2 (en) | 2015-08-21 | 2023-03-01 | Morphosys Ag | Combinations and their uses |
MA44909A (fr) | 2015-09-15 | 2018-07-25 | Acerta Pharma Bv | Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk |
AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
WO2017055328A1 (en) * | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-human cd19 antibodies with high affinity |
US10138298B2 (en) | 2015-10-23 | 2018-11-27 | The Regents Of The University Of California | Anti-IL-2 antibodies and compositions and uses thereof |
JP7141336B2 (ja) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
CN115932265A (zh) | 2016-05-30 | 2023-04-07 | 莫佛塞斯公司 | 预测cd19抗体治疗在患者中的治疗益处的方法 |
ES2963807T3 (es) | 2016-06-08 | 2024-04-02 | Xencor Inc | Tratamiento de enfermedades relacionadas con la IgG4 con anticuerpos anti-CD19 de reticulación a CD32B |
SI3475303T1 (sl) | 2016-06-27 | 2021-12-31 | Morphosys Ag | Formulacija protitelesa proti CD19 |
CN116271014A (zh) | 2016-08-05 | 2023-06-23 | 中外制药株式会社 | 用于预防或治疗il-8相关疾病的组合物 |
SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
CN109862919A (zh) | 2016-10-11 | 2019-06-07 | 免疫医疗有限公司 | 抗体-药物缀合物联合免疫介导的治疗剂 |
GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
LT3532098T (lt) | 2016-10-28 | 2021-06-25 | Morphosys Ag | Anti cd19 antikūno derinys su bcl-2 inhibitoriumi, ir jo naudojimas |
LT3544636T (lt) | 2017-02-08 | 2021-06-25 | Adc Therapeutics Sa | Pirolobenzodiazepino-antikūno konjugatai |
GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
EP3612537B1 (en) | 2017-04-18 | 2022-07-13 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
FI3630177T3 (fi) | 2017-05-31 | 2023-10-18 | Morphosys Ag | Hoitoparadigma anti-cd19-vasta-aineen ja venetoklaksin yhdistelmähoidolle |
WO2019011918A1 (en) | 2017-07-10 | 2019-01-17 | International - Drug - Development - Biotech | TREATMENT OF LYMPHOCYTE B MALIGNANCIES USING AFUCOSYLATED PRO-APOPTOTIC ANTI-CD19 ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES OR CHEMOTHERAPEUTIC AGENTS |
MX2020001880A (es) | 2017-08-18 | 2021-07-06 | Medimmune Ltd | Conjugados de pirrolobenzodiazepina. |
WO2019057100A1 (en) | 2017-09-21 | 2019-03-28 | Wuxi Biologics (Shanghai) Co., Ltd. | NEW ANTI-CD19 ANTIBODIES |
MA51154A (fr) * | 2017-12-15 | 2020-10-21 | Aleta Biotherapeutics Inc | Variants de cd19 |
GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
MX2020009296A (es) | 2018-03-15 | 2020-11-13 | Chugai Pharmaceutical Co Ltd | Anticuerpos anti-virus del dengue que tienen reactividad cruzada con el virus zika y metodos de uso. |
GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
WO2019224275A1 (en) | 2018-05-23 | 2019-11-28 | Adc Therapeutics Sa | Molecular adjuvant |
CN112566938A (zh) | 2018-06-03 | 2021-03-26 | 拉姆卡普生物测试有限公司 | 针对ceacam5和cd47的双特异性抗体 |
CN113272327A (zh) | 2018-12-30 | 2021-08-17 | 豪夫迈·罗氏有限公司 | 抗兔cd19抗体及其使用方法 |
CA3137664A1 (en) | 2019-05-03 | 2020-11-12 | Morphosys Ag | Anti-cd19 therapy in patients having a limited number of nk cells |
EP4038194A1 (en) | 2019-10-04 | 2022-08-10 | Ultragenyx Pharmaceutical Inc. | Methods for improved therapeutic use of recombinant aav |
AU2020376305A1 (en) | 2019-10-31 | 2022-05-12 | Incyte Corporation | Anti-CD19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma |
WO2021084064A1 (en) | 2019-10-31 | 2021-05-06 | Morphosys Ag | Sequential anti-cd19 therapy |
AU2020372646A1 (en) | 2019-10-31 | 2022-05-12 | Incyte Corporation | Anti-tumor combination therapy comprising anti-CD19 antibody and gamma delta T-cells |
EP3831849A1 (en) | 2019-12-02 | 2021-06-09 | LamKap Bio beta AG | Bispecific antibodies against ceacam5 and cd47 |
AU2020403913A1 (en) | 2019-12-18 | 2022-06-09 | F. Hoffmann-La Roche Ag | Bispecific anti-CCL2 antibodies |
EP3869302A1 (en) | 2020-02-18 | 2021-08-25 | Bayerische Motoren Werke Aktiengesellschaft | Vehicle, apparatus and method to reduce the occurence of motion sickness |
US11753413B2 (en) | 2020-06-19 | 2023-09-12 | Incyte Corporation | Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors |
WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
JP2023530499A (ja) | 2020-06-22 | 2023-07-18 | モルフォシス・アーゲー | 抗CD19抗体及びSIRPα-CD47自然免疫チェックポイントを遮断するポリペプチドを含む抗腫瘍組み合わせ療法 |
US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
BR112023000047A2 (pt) | 2020-07-02 | 2023-03-14 | Incyte Corp | Compostos de ureia tricíclicos como inibidores da v617f da jak2 |
US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
CA3194386A1 (en) | 2020-10-06 | 2022-04-14 | Ying Ding | Biomarkers, methods, and compositions for treating autoimmune disease including systemic lupus erythematous (sle) |
US20230372528A1 (en) | 2020-10-16 | 2023-11-23 | University Of Georgia Research Foundation, Inc. | Glycoconjugates |
TW202241436A (zh) | 2020-11-30 | 2022-11-01 | 美商英塞特公司 | 抗cd19抗體及帕薩昔布(parsaclisib)之組合療法 |
WO2022115120A1 (en) | 2020-11-30 | 2022-06-02 | Incyte Corporation | Combination therapy with an anti-cd19 antibody and parsaclisib |
TW202237184A (zh) | 2020-12-04 | 2022-10-01 | 德商莫菲西斯公司 | 抗cd19組合療法 |
JP2024501809A (ja) | 2020-12-18 | 2024-01-16 | ランカプ バイオ ベータ リミテッド | Ceacam5およびcd47に対する二重特異性抗体 |
US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
US11958861B2 (en) | 2021-02-25 | 2024-04-16 | Incyte Corporation | Spirocyclic lactams as JAK2 V617F inhibitors |
EP4326288A1 (en) | 2021-04-21 | 2024-02-28 | Indapta Therapeutics, Inc. | Methods of treatment and dosing of natural killer cell compositions |
WO2022263501A1 (en) | 2021-06-18 | 2022-12-22 | F. Hoffmann-La Roche Ag | Bispecific anti-ccl2 antibodies |
WO2023073645A1 (en) | 2021-10-29 | 2023-05-04 | Takeda Pharmaceutical Company Limited | Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor |
TW202334231A (zh) | 2021-12-22 | 2023-09-01 | 德商莫菲西斯公司 | 抗cd19抗體療法的治療範例 |
WO2023178285A1 (en) | 2022-03-17 | 2023-09-21 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
WO2023201339A1 (en) | 2022-04-15 | 2023-10-19 | Kyverna Therapeutics, Inc. | Methods and compositions for treating autoimmune disease |
WO2023240064A1 (en) | 2022-06-08 | 2023-12-14 | Kyverna Therapeutics, Inc. | Methods and compositions for treating autoimmune disease |
WO2023242351A1 (en) | 2022-06-16 | 2023-12-21 | Lamkap Bio Beta Ag | Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3 |
WO2024038115A1 (en) | 2022-08-17 | 2024-02-22 | Morphosys Ag | Therapy comprising anti-cd19 antibody and ezh2 modulators |
Family Cites Families (211)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US618965A (en) * | 1899-02-07 | Filter | ||
US2228904A (en) | 1939-05-10 | 1941-01-14 | Bjorkman Hugo Leonard | Wrench |
WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
EP0268636B1 (en) | 1986-05-29 | 1997-01-08 | Ilexus Pty Ltd | Polynucleotide sequences encoding the human FC RECEPTOR FOR IMMUNOGLOBULIN |
GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
PT88641B (pt) | 1987-10-02 | 1993-04-30 | Genentech Inc | Metodo para a preparacao de uma variante de adesao |
US5576184A (en) | 1988-09-06 | 1996-11-19 | Xoma Corporation | Production of chimeric mouse-human antibodies with specificity to human tumor antigens |
US5681566A (en) | 1988-10-24 | 1997-10-28 | 3I Research Exploitation Limited | Antibody conjugates with two or more covalently linked FC regions |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US20030229208A1 (en) | 1988-12-28 | 2003-12-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
JP3051411B2 (ja) | 1989-03-14 | 2000-06-12 | 持田製薬株式会社 | 新規dnaならびにそれを含有する発現プラスミド |
US5266491A (en) | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
AU648056B2 (en) | 1989-11-07 | 1994-04-14 | Bristol-Myers Squibb Company | Oligomeric immunoglobulins |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
AU7566991A (en) | 1990-03-14 | 1991-10-10 | Biomembrane Institute, The | Monoclonal antibody and immunoconjugates for the treatment and detection of b cell disorders |
WO1991019515A1 (en) | 1990-06-21 | 1991-12-26 | The Board Of Trustees Of The Leland Stanford Junior University | Oligomeric immunoglobulin constant domain mutant with enhanced complement-mediated cytolytic activity |
US5198342A (en) | 1990-07-05 | 1993-03-30 | Immunex Corporation | DNA encoding IgA Fc receptors |
CA2090317A1 (en) | 1990-08-31 | 1992-03-01 | Edith A. Wolff | Homoconjugated immunoglobulins |
GB9022545D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
GB9105245D0 (en) | 1991-03-12 | 1991-04-24 | Lynxvale Ltd | Binding molecules |
US6797492B2 (en) | 1991-05-17 | 2004-09-28 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
JPH07503124A (ja) | 1991-06-14 | 1995-04-06 | ゾーマ・コーポレーション | 微生物によって生産される抗体断片とそれらの複合体 |
US5264586A (en) | 1991-07-17 | 1993-11-23 | The Scripps Research Institute | Analogs of calicheamicin gamma1I, method of making and using the same |
JP3951062B2 (ja) | 1991-09-19 | 2007-08-01 | ジェネンテック・インコーポレーテッド | 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、2官能性F(ab’)2抗体の産生のための使用 |
US5623053A (en) | 1992-01-10 | 1997-04-22 | California Institute Of Technology | Soluble mammal-derived Fc receptor which binds at a pH ranging from about 5.5 to 6.5 and releases at a pH ranging from about 7.5 to 8.5 |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
US5686072A (en) * | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
EP0672142B1 (en) | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
US20030108548A1 (en) | 1993-06-01 | 2003-06-12 | Bluestone Jeffrey A. | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
GB9316989D0 (en) | 1993-08-16 | 1993-09-29 | Lynxvale Ltd | Binding molecules |
ATE240395T1 (de) | 1994-03-29 | 2003-05-15 | Celltech Therapeutics Ltd | Antikörper gegen e-selektin |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
JP3794701B2 (ja) | 1994-07-21 | 2006-07-12 | アクゾ ノーベル ナムローゼ フェンノートシャップ | 環状ケトン過酸化物処方 |
US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
US6485726B1 (en) | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
ATE238668T1 (de) | 1995-01-17 | 2003-05-15 | Brigham & Womens Hospital | Rezeptorspezifischer transepithelialer transport von immunogenen |
US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US6086875A (en) | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
WO1996030347A1 (en) | 1995-03-30 | 1996-10-03 | Pfizer Inc. | Quinazoline derivatives |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US6444789B1 (en) | 1995-05-03 | 2002-09-03 | Applied Research Systems Ars Holding N.V. | CD16-II variants |
WO1996036360A1 (en) | 1995-05-17 | 1996-11-21 | Regents Of The University Of Minnesota | Immunoconjugates comprising single-chain variable region fragments of anti-cd-19 antibodies |
US6365161B1 (en) | 1995-06-07 | 2002-04-02 | Medarex, Inc. | Therapeutic compounds comprised of anti-FC receptor binding agents |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
ATE267610T1 (de) | 1996-03-20 | 2004-06-15 | Immunomedics Inc | Glykosylierte igg antikörper |
BR9708640B1 (pt) | 1996-04-12 | 2013-06-11 | inibidores irreversÍveis de tirosina-cinases e composiÇço farmacÊutica compreendendo os mesmo. | |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
WO1998002462A1 (en) | 1996-07-16 | 1998-01-22 | Morphosys Gesellschaft Für Proteinoptimierung Mbh | Immunoglobulin superfamily domains and fragments with increased solubility |
ES2300113T3 (es) | 1996-08-02 | 2008-06-01 | Bristol-Myers Squibb Company | Un procedimiento para inhibir toxicidad inducida por inmunoglobulinas que resulta del uso de inmunoglobulinas en terapia y diagnostico in vivo. |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
WO1998031806A2 (en) | 1997-01-21 | 1998-07-23 | Human Genome Sciences, Inc. | Fc RECEPTORS AND POLYPEPTIDES |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
US6188965B1 (en) | 1997-04-11 | 2001-02-13 | California Institute Of Technology | Apparatus and method for automated protein design |
EP1255209A3 (en) | 1997-04-11 | 2009-02-11 | California Institute Of Technology | Apparatus and method for automated protein design |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US20040191256A1 (en) | 1997-06-24 | 2004-09-30 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
US20030105294A1 (en) | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
CA2323757C (en) | 1998-04-02 | 2011-08-02 | Genentech, Inc. | Antibody variants and fragments thereof |
EP2261229A3 (en) | 1998-04-20 | 2011-03-23 | GlycArt Biotechnology AG | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
ES2203141T3 (es) | 1998-04-21 | 2004-04-01 | Micromet Ag | Polipeptidos cd19 x cd3 especificos y su utilizacion. |
DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
WO1999056777A1 (en) | 1998-05-06 | 1999-11-11 | Temple University - Of The Commonwealth System Of Higher Education | REVERSAL OF PROINFLAMMATORY RESPONSE BY LIGATING THE MACROPHAGE FcηRI RECEPTOR |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
US20020142374A1 (en) | 1998-08-17 | 2002-10-03 | Michael Gallo | Generation of modified molecules with increased serum half-lives |
US6306926B1 (en) | 1998-10-07 | 2001-10-23 | 3M Innovative Properties Company | Radiopaque cationically polymerizable compositions comprising a radiopacifying filler, and method for polymerizing same |
CA2347214A1 (en) | 1998-10-16 | 2000-04-27 | Klaus M. Fiebig | Protein design automation for protein libraries |
US7315786B2 (en) | 1998-10-16 | 2008-01-01 | Xencor | Protein design automation for protein libraries |
US20030049654A1 (en) | 1998-10-16 | 2003-03-13 | Xencor | Protein design automation for protein libraries |
US20020048772A1 (en) | 2000-02-10 | 2002-04-25 | Dahiyat Bassil I. | Protein design automation for protein libraries |
US6403312B1 (en) | 1998-10-16 | 2002-06-11 | Xencor | Protein design automatic for protein libraries |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
NZ539776A (en) | 1999-01-15 | 2006-12-22 | Genentech Inc | Polypeptide variants with altered effector function |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
EP2270148A3 (en) | 1999-04-09 | 2011-06-08 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
EP1637160A3 (en) | 1999-05-07 | 2006-05-03 | Genentech, Inc. | Treatment of autoimmune diseases with antagonists which bind to B cell surface markers |
PT1194167E (pt) | 1999-06-09 | 2009-10-23 | Immunomedics Inc | Imunoterapia de doenças auto-imunitárias utilizando anticorpos que têm como alvo células b |
US6638515B2 (en) | 1999-09-07 | 2003-10-28 | Walter Schubert | Method of blocking cytotoxic activity in patients with amyotrophic lateral sclerosis using protein V |
AU7950400A (en) | 1999-10-19 | 2001-04-30 | Kyowa Hakko Kogyo Co. Ltd. | Process for producing polypeptide |
ES2568625T3 (es) | 1999-11-29 | 2016-05-03 | The Trustees Of Columbia University In The City Of New York | Aislamiento de cinco genes novedosos que codifican nuevos melanomas de tipo receptor de Fc implicados en la patogénesis del linfoma/melanoma |
DE19958134C2 (de) | 1999-12-02 | 2003-05-15 | Koenig & Bauer Ag | Saugwalze |
NZ520472A (en) | 2000-02-03 | 2004-03-26 | Lennart Hammarstrom | Ruminant MHC class I-like Fc receptors |
JP2003521933A (ja) | 2000-02-10 | 2003-07-22 | ゼンコー | タンパク質ライブラリーに関するタンパク質設計オートメーション |
ES2637801T3 (es) | 2000-04-11 | 2017-10-17 | Genentech, Inc. | Anticuerpos multivalentes y usos de los mismos |
US7416726B2 (en) | 2000-04-13 | 2008-08-26 | The Rockefeller University | Enhancement of antibody-mediated immune responses |
US6358733B1 (en) | 2000-05-19 | 2002-03-19 | Apolife, Inc. | Expression of heterologous multi-domain proteins in yeast |
DE60139689D1 (de) | 2000-06-22 | 2009-10-08 | Univ Iowa Res Found | Kombination von CpG und Antikörpern gegen CD19,CD20,CD22 oder CD40 zur Prävention oder Behandlung von Krebs. |
AU2001291175A1 (en) | 2000-09-21 | 2002-04-02 | Md Online Inc. | Medical image processing systems |
CA2424977C (en) | 2000-10-06 | 2008-03-18 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
ES2639222T5 (es) | 2000-10-06 | 2023-11-24 | Kyowa Kirin Co Ltd | Células que producen unas composiciones de anticuerpo |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
US6992234B2 (en) | 2000-11-06 | 2006-01-31 | The Jackson Laboratory | FcRn-based therapeutics for the treatment of auto-immune disorders |
US7235643B2 (en) | 2000-11-07 | 2007-06-26 | Morphotek, Inc. | Antibodies and methods for generating genetically altered antibodies with high affinity |
GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
US20040253242A1 (en) | 2000-12-05 | 2004-12-16 | Bowdish Katherine S. | Rationally designed antibodies |
EP2354149B1 (en) | 2000-12-12 | 2017-08-30 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
CA2430182C (en) | 2000-12-14 | 2011-01-25 | Genentech, Inc. | Prokaryotically produced antibodies and uses thereof |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
WO2002061093A1 (en) | 2001-01-30 | 2002-08-08 | Degussa Ag | Nucleotide sequences which code for the otsa gene of c. glutamicum |
US20030103971A1 (en) | 2001-11-09 | 2003-06-05 | Kandasamy Hariharan | Immunoregulatory antibodies and uses thereof |
CN100574803C (zh) | 2001-01-31 | 2009-12-30 | 拜奥根Idec公司 | 免疫调节抗体在治疗肿瘤性疾病中的用途 |
WO2002080987A1 (en) | 2001-04-09 | 2002-10-17 | Progenics Pharmaceuticals, Inc. | Anti-cd19 immunotoxins |
CN101671335A (zh) | 2001-05-31 | 2010-03-17 | 梅达莱克斯公司 | 细胞毒素、其有用的前体药物、连接基团和稳定剂 |
GB0118662D0 (en) | 2001-07-31 | 2001-09-19 | Univ Southampton | Binding agents |
CN1555411A (zh) | 2001-08-03 | 2004-12-15 | ���迨�����\���ɷݹ�˾ | 抗体-依赖性细胞毒性增大的抗体糖基化变体 |
EP1432980A4 (en) | 2001-08-10 | 2006-04-12 | Xencor Inc | AUTOMATED PROTEIN CONSTRUCTION FOR PROTEIN LIBRARIES |
US7255858B2 (en) | 2001-08-10 | 2007-08-14 | University Of Virginia Patent Foundation | Enhancing the efficacy of immunotherapies by supplementing with complement |
ES2276735T3 (es) | 2001-09-14 | 2007-07-01 | Affimed Therapeutics Ag | Anticuerpos fv multimericos de cadena sencilla en tandem. |
HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
EP1314741B1 (en) | 2001-11-14 | 2007-03-07 | Affimed Therapeutics AG | Bispecific anti-CD19 x anti-CD16 antibodies and uses thereof |
US6911321B2 (en) | 2001-12-19 | 2005-06-28 | Genentech, Inc. | Non-human primate Fc receptors and methods of use |
AU2003216250A1 (en) | 2002-02-11 | 2003-09-04 | Genentech, Inc. | Antibody variants with faster antigen association rates |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
US20080260731A1 (en) | 2002-03-01 | 2008-10-23 | Bernett Matthew J | Optimized antibodies that target cd19 |
CN101143221A (zh) | 2002-03-15 | 2008-03-19 | 布赖汉姆妇女医院 | 适合治疗剂全身性递送的中央气道给药 |
US7317087B2 (en) | 2002-03-25 | 2008-01-08 | The Uab Research Foundation | Members of the FC receptor homolog gene family (FCRH1-3, 6), related reagents, and uses thereof |
CA2481658A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to fcy receptor iiia |
EP1354600A1 (en) | 2002-04-19 | 2003-10-22 | Affimed Therapeutics AG | Antibody combination useful for tumor therapy |
WO2004004798A2 (en) | 2002-07-03 | 2004-01-15 | The Brigham And Women's Hospital, Inc. | Central airway administration for systemic delivery of therapeutics |
JP2006500009A (ja) | 2002-07-09 | 2006-01-05 | ジェネンテック・インコーポレーテッド | 腫瘍の診断と治療のための組成物と方法 |
CA2495251C (en) | 2002-08-14 | 2018-03-06 | Macrogenics, Inc. | Fc.gamma.riib-specific antibodies and methods of use thereof |
WO2004022717A2 (en) | 2002-09-05 | 2004-03-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Minimally immunogenic variants of humanized col-1 antibody against carcinoembryonic antigen |
CA2499075A1 (en) | 2002-09-16 | 2004-03-25 | Elusys Therapeutics, Inc. | Production of bispecific molecules using polyethylene glycol linkers |
CA2502904C (en) | 2002-10-15 | 2013-05-28 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
US7365168B2 (en) | 2002-10-15 | 2008-04-29 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
EP1944320A1 (en) | 2002-12-16 | 2008-07-16 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
US7534427B2 (en) | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
AU2004204494B2 (en) | 2003-01-09 | 2011-09-29 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
JP4869064B2 (ja) | 2003-04-04 | 2012-02-01 | ジェネンテック, インコーポレイテッド | 高濃度抗体及びタンパク質製剤 |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
WO2004110498A2 (en) | 2003-05-14 | 2004-12-23 | Immunogen, Inc. | Drug conjugate composition |
AR044388A1 (es) | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
AU2004257142A1 (en) | 2003-05-30 | 2005-01-27 | Alexion Pharmaceuticals, Inc. | Antibodies and fusion proteins that include engineered constant regions |
AU2004242846A1 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders |
WO2004110472A2 (en) | 2003-06-12 | 2004-12-23 | Eli Lilly And Company | Fusion proteins |
CA2529945A1 (en) | 2003-06-27 | 2005-01-06 | Biogen Idec Ma Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
EP1644416A4 (en) | 2003-06-30 | 2007-08-29 | Centocor Inc | ANTI-TARGET AND GENETICALLY MODIFIED IMMUNOGLOBULIN-DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES |
KR101299599B1 (ko) | 2003-07-24 | 2013-08-23 | 위니베르시따 데글리 스뚜디 디 뻬루지아 | Nk 세포 강화 화합물을 사용하여 치료용 항체의 효율을 높이는 방법 및 조성물 |
WO2005011376A2 (en) | 2003-07-26 | 2005-02-10 | Biogen Idec Ma Inc | Altered antibodies having improved antigen-binding affinity |
EP1648512A4 (en) | 2003-07-31 | 2009-01-21 | Immunomedics Inc | ANTI-CD19 ANTIBODIES |
US20080050357A1 (en) | 2003-08-01 | 2008-02-28 | Claes Gustafsson | Systems and Methods for Antibody Engineering |
CA2536408A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
CA2534959A1 (en) | 2003-09-05 | 2005-03-31 | Genentech, Inc. | Antibodies with altered effector functions |
WO2005023866A2 (en) | 2003-09-10 | 2005-03-17 | Baxter International Inc. | Peptides that inhibit complement activation |
WO2005037867A1 (en) | 2003-10-15 | 2005-04-28 | Pdl Biopharma, Inc. | ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG |
GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
JP2008504002A (ja) | 2003-11-12 | 2008-02-14 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 新生児Fcレセプター(FcRn)結合ポリペプチド改変体、ダイマーFc結合タンパク質、およびそれらに関連する方法 |
WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
AU2004293182B2 (en) | 2003-11-28 | 2010-02-18 | Amgen Research (Munich) Gmbh | Compositions comprising polypeptides |
JP4762156B2 (ja) | 2004-01-12 | 2011-08-31 | アプライド モレキュラー エボリューション,インコーポレイテッド | Fc領域変異体 |
WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
KR100545720B1 (ko) | 2004-05-31 | 2006-01-24 | 메덱스젠 주식회사 | 당화된 면역글로불린 및 이를 포함하는 면역접합체 |
AU2005267020B2 (en) | 2004-07-23 | 2011-08-11 | Genentech, Inc. | Crystallization of antibodies or fragments thereof |
WO2006047350A2 (en) * | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
JP5651285B2 (ja) | 2005-02-15 | 2015-01-07 | デューク ユニバーシティ | 抗cd19抗体および腫瘍学における使用 |
AU2006244445B2 (en) | 2005-05-05 | 2013-04-18 | Duke University | Anti-CD19 antibody therapy for autoimmune disease |
EP1904101A4 (en) | 2005-06-08 | 2011-06-15 | Univ Duke | ANTI-CD19 ANTIBODY THERAPY FOR TRANSPLANTATION |
US8097703B2 (en) | 2005-06-20 | 2012-01-17 | Medarex, Inc. | CD19 antibodies and their uses |
RU2008129080A (ru) | 2005-12-16 | 2010-01-27 | Микромет Аг (De) | Средства и способы лечения опухолевых заболеваний |
JP2009521912A (ja) | 2005-12-30 | 2009-06-11 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 低減された免疫原性を有する抗cd19抗体 |
US20070166306A1 (en) | 2006-01-17 | 2007-07-19 | Fey Georg H M | Anti-CD19 antibody composition and method |
US20070178103A1 (en) | 2006-01-30 | 2007-08-02 | Fey Georg H | CD19-specific immunotoxin and treatment method |
ME01786B (me) | 2006-08-14 | 2014-09-20 | Xencor Inc | Optimizovana antitela usmerena na cd19 |
PL2066349T3 (pl) | 2006-09-08 | 2012-09-28 | Medimmune Llc | Humanizowane przeciwciała anty-CD19 i ich zastosowanie w leczeniu nowotworów, transplantacjach i leczeniu chorób autoimmunologicznych |
US20080267977A1 (en) | 2007-04-26 | 2008-10-30 | Friedrich-Alexander University Of Erlangen-Nuremberg | Combined immunological agent and sensitizing agent for the treatment of cancer |
EP2176298B1 (en) * | 2007-05-30 | 2017-11-15 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
US9098105B2 (en) | 2012-08-24 | 2015-08-04 | Avago Technologies General Ip (Singapore) Pte. Ltd. | Dynamic Y-buffer size adjustment for retained sector reprocessing |
US9679104B2 (en) | 2013-01-17 | 2017-06-13 | Edico Genome, Corp. | Bioinformatics systems, apparatuses, and methods executed on an integrated circuit processing platform |
US9703321B2 (en) | 2013-07-09 | 2017-07-11 | I-Blades, Inc. | Snap on wearable module |
US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
US11392902B2 (en) | 2017-06-06 | 2022-07-19 | United Parcel Service Of America, Inc. | Systems, methods, apparatuses and computer program products for providing notification of items for pickup and delivery |
-
2007
- 2007-08-14 ME MEP-2014-35A patent/ME01786B/me unknown
- 2007-08-14 SI SI200731159T patent/SI2383297T1/sl unknown
- 2007-08-14 EP EP07840953.9A patent/EP2059536B1/en active Active
- 2007-08-14 PL PL11173336T patent/PL2383297T3/pl unknown
- 2007-08-14 ES ES07840953.9T patent/ES2457072T3/es active Active
- 2007-08-14 PT PT78409539T patent/PT2059536E/pt unknown
- 2007-08-14 CA CA2658557A patent/CA2658557C/en active Active
- 2007-08-14 PL PL07840953T patent/PL2059536T3/pl unknown
- 2007-08-14 JP JP2009524772A patent/JP5825756B2/ja active Active
- 2007-08-14 WO PCT/US2007/075932 patent/WO2008022152A2/en active Application Filing
- 2007-08-14 PT PT111733366T patent/PT2383297E/pt unknown
- 2007-08-14 DK DK07840953.9T patent/DK2059536T3/da active
- 2007-08-14 ES ES11173336T patent/ES2402591T3/es active Active
- 2007-08-14 US US12/377,251 patent/US8524867B2/en active Active
- 2007-08-14 RS RS20130134A patent/RS52775B9/sr unknown
- 2007-08-14 AU AU2007285976A patent/AU2007285976B2/en active Active
- 2007-08-14 RS RS20140165A patent/RS53263B/en unknown
- 2007-08-14 DK DK11173336.6T patent/DK2383297T5/da active
- 2007-08-14 EP EP11173336.6A patent/EP2383297B8/en active Active
- 2007-08-14 SI SI200731437T patent/SI2059536T1/sl unknown
-
2009
- 2009-11-20 HK HK09110913.4A patent/HK1131168A1/xx unknown
-
2011
- 2011-05-06 JP JP2011103488A patent/JP5645747B2/ja active Active
- 2011-08-30 US US13/221,811 patent/US20120082664A1/en not_active Abandoned
-
2013
- 2013-04-05 HR HRP20130314TT patent/HRP20130314T2/hr unknown
- 2013-06-04 JP JP2013118273A patent/JP2013177443A/ja active Pending
- 2013-08-05 US US13/959,587 patent/US9803020B2/en active Active
- 2013-09-10 US US14/023,305 patent/US20140112916A1/en not_active Abandoned
-
2014
- 2014-04-07 HR HRP20140331TT patent/HRP20140331T1/hr unknown
-
2015
- 2015-09-11 JP JP2015179854A patent/JP2015221839A/ja active Pending
-
2017
- 2017-09-22 US US15/712,918 patent/US10626182B2/en active Active
-
2020
- 2020-04-01 US US16/837,678 patent/US11618788B2/en active Active
-
2022
- 2022-02-18 FR FR22C1007C patent/FR22C1007I2/fr active Active
- 2022-02-18 HU HUS2200007C patent/HUS2200007I1/hu unknown
- 2022-02-21 FI FIC20220006C patent/FIC20220006I1/fi unknown
- 2022-02-22 NL NL301163C patent/NL301163I2/nl unknown
- 2022-02-24 LT LTPA2022503C patent/LTPA2022503I1/lt unknown
-
2023
- 2023-02-21 US US18/172,196 patent/US20230340144A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS2200007I1 (hu) | CD19-re irányuló optimalizált antitestek | |
IL194995A0 (en) | Modified humanised anti-interleukin-18 antibodies | |
ZA200904022B (en) | Monoclonal antibodies against ANGPTL3 | |
ZA201306383B (en) | Crystalline anti-htnfalpha antibodies | |
GB0708002D0 (en) | Antibodies | |
IL205502A0 (en) | Humanized antibodies against tl1a | |
EP2051097A4 (en) | RADAR | |
IL196022A0 (en) | Glyco-engineered antibodies | |
GB0615662D0 (en) | Antibody | |
PL2011869T3 (pl) | Nowe przeciwciało anty-CD98 | |
IL200168A0 (en) | Monoclonal anti-cxcl13 antibodies | |
GB0517487D0 (en) | Antibodies | |
GB0718737D0 (en) | Antibodies | |
EP2160407A4 (en) | NEUTRALIZING ANTIBODIES | |
GB0714011D0 (en) | Radar aaparatus | |
GB0609979D0 (en) | Target | |
EP2015785A4 (en) | ANTIGEN AGRM2 | |
EP1896047A4 (en) | ANTI-GFRALPHA3 ANTIBODIES | |
GB0505489D0 (en) | Antibodies | |
GB0601059D0 (en) | Target | |
GB0512278D0 (en) | Antibodies | |
GB0505054D0 (en) | Antibodies | |
GB0607376D0 (en) | Antibodies | |
GB0606276D0 (en) | Antibodies | |
GB0724185D0 (en) | Antibodies |